https://doi.org/10.4081/aiua.2022.4.464

Testosterone deficiency in non-obese type 2 diabetic male patients

Vol. 94 No. 4 (2022)
Submitted: March 5, 2022
Accepted: April 2, 2022
Published: December 27, 2022
Non-obese, T2DM, Visceral obesity, Testosterone, VAI, Males
Abstract Views: 653
PDF: 380
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Sherihan I. Gouda
Endocrinology and Diabetes Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed M. Aboelnaga
dr.mhd.endocrine@gmail.com
Endocrinology and Diabetes Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Ahmed M.G. Elbeltagy
Clinical Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Amro Elbaz
Endocrinology and Diabetes Unit, Faculty of Medicine, Mansoura University, Mansoura, Egypt.

Background and aims: it is unclear whether male hypogonadism is ascribable to the diabetic state per se, or because of other factors, such as obesity or age. We aimed to investigate the prevalence and identify the predictors for testosterone deficiency among non-obese type 2 diabetic males.
Methods: This cross-sectional study was conducted on 95 nonobese type 2 diabetic males with BMI below 30. We evaluated the total testosterone (TT) levels to determine prevalence and risk factors of testosterone deficiency. Serum TT ≤ 300 ng/dl defined testosterone deficiency.
Results: The prevalence of testosterone deficiency was 29.1%. Testosterone deficient patients had statistically significantly higher visceral adiposity index (VAI), waist, and triglyceride in comparison with normal testosterone patients. TT level correlated with VAI, waist, BMI, LH, and age. VAI was the only significant predictor of TT levels even after adjustment for age and BMI in regression analysis. Furthermore, VAI was a statistically significant risk factor for testosterone deficiency in binary logistic analysis.
Conclusions: testosterone deficient non-obese type 2 diabetic male patients had elevated VAI, waist, and triglyceride. Moreover, elevated VAI was a risk factor for testosterone deficiency. VAI could be an easily applicable and reliable index for the evaluation and prediction in type 2 non-obese diabetic males.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Hassan M, Hatata EZ, Al-Arman M, Aboelnaga MM. Urinary cystatin C as a biomarker of early renal dysfunction in type 2 diabetic patients [published online ahead of print, 2021 May 25]. Diabetes Metab Syndr. 2021;15(4):102152. doi:10.1016/j.dsx.2021.05.025. DOI: https://doi.org/10.1016/j.dsx.2021.05.025
Gianatti EJ, Grossmann M. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. Diabet Med. 2020;37(2):174-186. doi:10.1111/dme.13977
Anupam B, Shivaprasad C, Vijaya S, Sridevi A, Aiswarya Y, Nikhil K. Prevalence of hypogonadism in patients with type 2 diabetes mellitus among the Indian population. Diabetes Metab Syndr. 2020;14(5):1299-1304. doi:10.1016/j.dsx.2020.07.006
Gianatti EJ, Grossmann M. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. Diabet Med. 2020;37(2):174-186. doi:10.1111/dme.13977.
Castellano-Castillo D, Royo JL, Martínez-Escribano A, et al. Effects of SHBG rs1799941 Polymorphism on Free Testosterone Levels and Hypogonadism Risk in Young Non-Diabetic Obese Males. J Clin Med. 2019;8(8):1136. Published 2019 Jul 31. doi:10.3390/jcm8081136. DOI: https://doi.org/10.3390/jcm8081136
Gianatti EJ, Grossmann M. Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. Diabet Med. 2020;37(2):174-186. doi:10.1111/dme.13977 DOI: https://doi.org/10.1111/dme.13977
Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96(8):2341-2353. doi:10.1210/jc.2011-0118. DOI: https://doi.org/10.1210/jc.2011-0118
Mozafar Saadati H, Sabour S, Mansournia MA, Mehrabi Y, Hashemi Nazari SS. Effect modification of general and central obesity by sex and age on cardiovascular outcomes: Targeted maximum likelihood estimation in the atherosclerosis risk in communities study. Diabetes Metab Syndr. 2021;15(2):479-485. doi:10.1016/j.dsx.2021.02.024 DOI: https://doi.org/10.1016/j.dsx.2021.02.024
Fernandez CJ, Chacko EC, Pappachan JM. Male Obesity-related Secondary Hypogonadism - Pathophysiology, Clinical Implications and Management. Eur Endocrinol. 2019;15(2):83-90. doi:10.17925/EE.2019.15.2.83 DOI: https://doi.org/10.17925/EE.2019.15.2.83
Lee DM, O'Neill TW, Pye SR, et al. The European Male Ageing Study (EMAS): design, methods and recruitment. Int J Androl. 2009;32(1):11-24. doi:10.1111/j.1365-2605.2008.00879.x DOI: https://doi.org/10.1111/j.1365-2605.2008.00879.x
Ng Tang Fui M, Hoermann R, Cheung AS, Gianatti EJ, Zajac JD, Grossmann M. Obesity and age as dominant correlates of low testosterone in men irrespective of diabetes status. Andrology. 2013;1(6):906-912. doi:10.1111/j.2047-2927.2013.00124.x DOI: https://doi.org/10.1111/j.2047-2927.2013.00124.x
Amato MC, Giordano C, Galia M, et al. Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33(4):920-922. doi:10.2337/dc09-1825 DOI: https://doi.org/10.2337/dc09-1825
Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2021 Jun 16;106(7):e2848]. J Clin Endocrinol Metab. 2010;95(6):2536-2559. doi:10.1210/jc.2009-2354 DOI: https://doi.org/10.1210/jc.2009-2354
Tajar A, Forti G, O'Neill TW, Lee DM, Silman AJ, Finn JD, Bartfai G, Boonen S, Casanueva FF, Giwercman A, Han TS, Kula K, Labrie F, Lean ME, Pendleton N, Punab M, Vanderschueren D, Huhtaniemi IT, Wu FC; EMAS Group. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010 Apr;95(4):1810-8. doi: 10.1210/jc.2009-1796. Epub 2010 Feb 19. PMID: 20173018.00.
Ganesh HK, Vijaya Sarathi HA, George J, et al. Prevalence of hypogonadism in patients with type 2 diabetes mellitus in an Asian Indian study group. Endocr Pract. 2009;15(6):513-520. doi:10.4158/EP09035.ORR DOI: https://doi.org/10.4158/EP09035.ORR
Al-Goblan AS, Al-Alfi MA, Khan MZ. Mechanism linking diabetes mellitus and obesity. Diabetes Metab Syndr Obes. 2014;7:587-591. Published 2014 Dec 4. doi:10.2147/DMSO.S67400 DOI: https://doi.org/10.2147/DMSO.S67400
Turan E, Öztekin Ü. Relationship between visceral adiposity index and male infertility. Andrologia. 2020;52(4):e13548. doi:10.1111/and.13548 DOI: https://doi.org/10.1111/and.13548
Haymana C, Sonmez A, Aydogdu A, et al. Visceral adiposity index and triglyceride/high-density lipoprotein cholesterol ratio in hypogonadism. Arch Endocrinol Metab. 2017;61(3):282-287. doi:10.1590/2359-3997000000236. DOI: https://doi.org/10.1590/2359-3997000000236
Akdemir AO, Karabakan M, Aktas BK, et al. Visceral adiposity index is useful for evaluating obesity effect on erectile dysfunction. Andrologia. 2019;51(6):e13282. doi:10.1111/and.13282. DOI: https://doi.org/10.1111/and.13282
Dursun M, Besiroglu H, Cakir SS, Otunctemur A, Ozbek E. Increased visceral adiposity index associated with sexual dysfunction in men. Aging Male. 2018;21(3):187-192. doi:10.1080/13685538.2017.1406468... DOI: https://doi.org/10.1080/13685538.2017.1406468
Ghazi S, Zohdy W, Elkhiat Y, Shamloul R. Serum testosterone levels in diabetic men with and without erectile dysfunction. Andrologia. 2012;44(6):373-380. doi:10.1111/j.1439-0272.2012.01292.x. DOI: https://doi.org/10.1111/j.1439-0272.2012.01292.x
Al Hayek AA, Khader YS, Jafal S, Khawaja N, Robert AA, Ajlouni K. Prevalence of low testosterone levels in men with type 2 diabetes mellitus: a cross-sectional study. J Family Community Med. 2013;20(3):179-186. doi:10.4103/2230-8229.122006. DOI: https://doi.org/10.4103/2230-8229.122006
Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl. 2014;16(2):223-231. doi:10.4103/1008-682X.122365 DOI: https://doi.org/10.4103/1008-682X.122365
Anupam B, Shivaprasad C, Vijaya S, Sridevi A, Aiswarya Y, Nikhil K. Prevalence of hypogonadism in patients with type 2 diabetes mellitus among the Indian population. Diabetes Metab Syndr. 2020;14(5):1299-1304. doi:10.1016/j.dsx.2020.07.006. DOI: https://doi.org/10.1016/j.dsx.2020.07.006
Tajar A, Forti G, O'Neill TW, et al. Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study. J Clin Endocrinol Metab. 2010;95(4):1810-1818. doi:10.1210/jc.2009-1796 . DOI: https://doi.org/10.1210/jc.2009-1796
Zheng R, Cao L, Cao W, et al. Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes. J Diabetes Res. 2016;2016:5162167. doi:10.1155/2016/5162167
Rendong Zheng, Lin Cao, Wen Cao, Xiaoqiu Chu, Yongxin Hu, Huifeng Zhang, Juan Xu, Hongping Sun, Weiping Bao, Kemian Liu, Chao Liu, "Risk Factors for Hypogonadism in Male Patients with Type 2 Diabetes", Journal of Diabetes Research, vol. 2016, Article ID 5162167, 8 pages, 2016. https://doi.org/10.1155/2016/5162167 DOI: https://doi.org/10.1155/2016/5162167
Cai X, Tian Y, Wu T, Cao CX, Li H, Wang KJ. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian J Androl. 2014;16(1):146-152. doi:10.4103/1008-682X.122346. DOI: https://doi.org/10.4103/1008-682X.122346
Fukui M, Tanaka M, Hasegawa G, Yoshikawa T, Nakamura N. Association between serum bioavailable testosterone concentration and the ratio of glycated albumin to glycated hemoglobin in men with type 2 diabetes. Diabetes Care. 2008;31(3):397-401. doi:10.2337/dc07-1898 DOI: https://doi.org/10.2337/dc07-1898
Šimonienė D, Platūkiene A, Prakapienė E, Radzevičienė L, Veličkiene D. Insulin Resistance in Type 1 Diabetes Mellitus and Its Association with Patient's Micro- and Macrovascular Complications, Sex Hormones, and Other Clinical Data. Diabetes Ther. 2020;11(1):161-174. doi:10.1007/s13300-019-00729-5 DOI: https://doi.org/10.1007/s13300-019-00729-5
Blaya R, Blaya P, Rhoden L, Rhoden EL. Low Testosterone Levels and Metabolic Syndrome in Aging Male. Curr Pharm Des. 2017;23(30):4470-4474. doi:10.2174/1381612823666170503150955.
Dandona P, Dhindsa S. Update: Hypogonadotropic hypogonadism in type 2 diabetes and obesity. J Clin Endocrinol Metab. 2011;96(9):2643-2651. doi:10.1210/jc.2010-2724. DOI: https://doi.org/10.1210/jc.2010-2724
Watanobe H, Hayakawa Y. Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology. 2003;144(11):4868-4875. doi:10.1210/en.2003-0644. DOI: https://doi.org/10.1210/en.2003-0644
Brüning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science. 2000;289(5487):2122-2125. doi:10.1126/science.289.5487.2122. DOI: https://doi.org/10.1126/science.289.5487.2122
Elsaied MA, Masallat D, Abdel-Hamid IA. Correlation of Adiponectin With Testosterone in Patients With and Without Type 2 Diabetes and Erectile Dysfunction. Am J Mens Health. 019;13(1):1557988318807049. doi:10.1177/1557988318807049. DOI: https://doi.org/10.1177/1557988318807049
C. Langer, B. Gansz, C. Goepfert et al., “Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages,” Biochemical and Biophysical Research Communications, vol. 296, no. 5, pp. 1051–1057, 2002. DOI: https://doi.org/10.1016/S0006-291X(02)02038-7
Feingold KR, Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins. In: Feingold KR, Anawalt B, Boyce A, et al., eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; January 8, 2019.
Ji B, Qu H, Wang H, Wei H, Deng H. Association Between the Visceral Adiposity Index and Homeostatic Model Assessment of Insulin Resistance in Participants With Normal Waist Circumference. Angiology. 2017;68(8):716-721. doi:10.1177/0003319716682120. DOI: https://doi.org/10.1177/0003319716682120
Štěpánek L, Horáková D, Cibičková Ľ, et al. Can Visceral Adiposity Index Serve as a Simple Tool for Identifying Individuals with Insulin Resistance in Daily Clinical Practice?. Medicina (Kaunas). 2019;55(9):545. Published 2019 Aug 29. doi:10.3390/medicina55090545. DOI: https://doi.org/10.3390/medicina55090545
Amato MC, Pizzolanti G, Torregrossa V, Misiano G, Milano S, Giordano C. Visceral adiposity index (VAI) is predictive of an altered adipokine profile in patients with type 2 diabetes. PLoS One. 2014;9(3):e91969. Published 2014 Mar 20. doi:10.1371/journal.pone.0091969 DOI: https://doi.org/10.1371/journal.pone.0091969
Al-Daghri NM, Al-Attas OS, Alokail MS, et al. Visceral adiposity index is highly associated with adiponectin values and glycaemic disturbances. Eur J Clin Invest. 2013;43(2):183-189. doi:10.1111/eci.12030 DOI: https://doi.org/10.1111/eci.12030
Wang, N., Zhai, H., Han, B. et al. Visceral fat dysfunction is positively associated with hypogonadism in Chinese men. Sci Rep 6, 19844 (2016). https://doi.org/10.1038/srep19844 DOI: https://doi.org/10.1038/srep19844
46. Blaya R, Blaya P, Rhoden L, Rhoden EL. Low Testosterone Levels and Metabolic Syndrome in Aging Male. Curr Pharm Des. 2017;23(30):4470-4474. doi:10.2174/1381612823666170503150955. DOI: https://doi.org/10.2174/1381612823666170503150955
Grossmann M, Hamilton EJ, Gilfillan C, Bolton D, Joon DL, Zajac JD. Bone and metabolic health in patients with non-metastatic prostate cancer who are receiving androgen deprivation therapy. Med J Aust. 2011;194(6):301-306. doi:10.5694/j.1326-5377.2011.tb02979.x DOI: https://doi.org/10.5694/j.1326-5377.2011.tb02979.x
Pekgor S, Duran C, Berberoglu U, Eryilmaz MA. The Role of Visceral Adiposity Index Levels in Predicting the Presence of Metabolic Syndrome and Insulin Resistance in Overweight and Obese Patients. Metab Syndr Relat Disord. 2019;17(5):296-302. doi:10.1089/met.2019.0005 DOI: https://doi.org/10.1089/met.2019.0005
Aboelnaga EM, Aboelnaga MM, Elkalla HM. Metformin addition to androgen deprivation therapy effect on cancer prostate patients with type 2 diabetes [published online ahead of print, 2021 Aug 18]. Diabetes Metab Syndr. 2021;15(5):102251. doi:10.1016/j.dsx.2021.102251 DOI: https://doi.org/10.1016/j.dsx.2021.102251

How to Cite

Gouda, S. I., Aboelnaga, M. M., Elbeltagy, A. M., & Elbaz, A. (2022). Testosterone deficiency in non-obese type 2 diabetic male patients. Archivio Italiano Di Urologia E Andrologia, 94(4), 464–469. https://doi.org/10.4081/aiua.2022.4.464
Copyright (c) 2022 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.